で公開中です！ 詳しく見る
PBYIのアイコン

Puma Biotechnology
PBYI

9.83 USD
-0.69
6.56%
終値時点 更新済み 10月16日 16:00 EDT
1日
-6.56%
5日間
-4.75%
1か月
4.69%
3か月
17.02%
6か月
35.77%
年初来
70.36%
1年
81.7%
5年間
66.05%
10年間
-81.2%
 

概要： Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

従業員数： 179

ヘルスケア バイオテクノロジー

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 31.3%
ニュートラル 62.5%
ネガティブ 6.3%
ポジティブ
Zacks Investment Research
13 時間前
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
AZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
ニュートラル
Business Wire
11 日前
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced the grant of an inducement award to one new hire in Sept. 2026, as required under Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
ニュートラル
Zacks Investment Research
28 日前
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
ニュートラル
Business Wire
29 日前
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology has initiated ALISCA®-Lung2, a Phase II trial of alisertib in combination with paclitaxel to treat advanced small cell lung cancer.
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
ニュートラル
Business Wire
先月
Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference
LOS ANGELES--(BUSINESS WIRE)--On Sept. 14, 2026, Puma Biotechnology CEO Alan Auerbach will present a corporate overview at H.C. Wainwright's 28th Annual Global Investment Conf.
Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference
ポジティブ
Seeking Alpha
先月
Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise
NERLYNX gives PBYI an established revenue stream that can support alisertib's development into a potential second oncology franchise. Currently, PBYI already has positive cash flows and a healthy balance sheet, which I believe should give them flexibility as their R&D progresses. Alisertib's biomarker strategy could identify responsive patients, but bear in mind that it's still a speculative asset in Phase 2 trials.
Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise
ニュートラル
Business Wire
先月
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported its inducement awards granted in August 2026, as required under Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
ポジティブ
Zacks Investment Research
2 か月前
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
ポジティブ
Zacks Investment Research
2 か月前
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
ニュートラル
Seeking Alpha
2 か月前
Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript
Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript
Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript
ニュースランキングを見る
価格チャートは Lightweight Charts™ を使用して実装されています